New antibiotics in clinical pipeline for treating infections caused by metallo-β-lactamases producing Gram-negative bacteria.

IF 3.6 3区医学 Q2 INFECTIOUS DISEASES

Current Opinion in Infectious Diseases Pub Date : 2024-12-01 Epub Date: 2024-09-12 DOI:10.1097/QCO.0000000000001056

Matteo Bassetti, Antonio Vena, Barbara Larosa, Daniele Roberto Giacobbe

{"title":"New antibiotics in clinical pipeline for treating infections caused by metallo-β-lactamases producing Gram-negative bacteria.","authors":"Matteo Bassetti, Antonio Vena, Barbara Larosa, Daniele Roberto Giacobbe","doi":"10.1097/QCO.0000000000001056","DOIUrl":null,"url":null,"abstract":"Purpose of review: To discuss novel antibiotics under clinical development, focusing on agents showing in-vitro activity against metallo-β-lactamases (MBL)-producing carbapenem-resistant Gram-negative bacteria (CR-GNB).Recent findings: Currently, only a few approved agents show activity, alone or in synergistic combinations, against MBL-producing CR-GNB. If approved by regulatory agencies in case of favorable results from ongoing (and, for some agents, already completed) phase-3 studies, some novel β-lactam/β-lactamase inhibitor (BL/BLI) combinations could become available in the next few years as additional important options for treating MBL-producing CR-GNB infections. Additional interesting agents that belong both to BL/BLI combinations and to antibiotic classes other than BL and BL/BLI combinations have also shown activity against MBL-producing CR-GNB, with most of them being in early phases of clinical development.Summary: Improving the use of these novel agents through virtuous antimicrobial stewardship frameworks able to guarantee both the efficacious treatment of infections requiring their use and the avoidance of their use whenever not necessary remains a challenge of utmost importance that should not be overlooked.","PeriodicalId":10880,"journal":{"name":"Current Opinion in Infectious Diseases","volume":" ","pages":"582-588"},"PeriodicalIF":3.6000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11556884/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Opinion in Infectious Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/QCO.0000000000001056","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/12 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: To discuss novel antibiotics under clinical development, focusing on agents showing in-vitro activity against metallo-β-lactamases (MBL)-producing carbapenem-resistant Gram-negative bacteria (CR-GNB).

Recent findings: Currently, only a few approved agents show activity, alone or in synergistic combinations, against MBL-producing CR-GNB. If approved by regulatory agencies in case of favorable results from ongoing (and, for some agents, already completed) phase-3 studies, some novel β-lactam/β-lactamase inhibitor (BL/BLI) combinations could become available in the next few years as additional important options for treating MBL-producing CR-GNB infections. Additional interesting agents that belong both to BL/BLI combinations and to antibiotic classes other than BL and BL/BLI combinations have also shown activity against MBL-producing CR-GNB, with most of them being in early phases of clinical development.

Summary: Improving the use of these novel agents through virtuous antimicrobial stewardship frameworks able to guarantee both the efficacious treatment of infections requiring their use and the avoidance of their use whenever not necessary remains a challenge of utmost importance that should not be overlooked.

查看原文本刊更多论文

用于治疗产生金属-β-内酰胺酶的革兰氏阴性菌引起的感染的新型抗生素已进入临床试验阶段。

综述目的：讨论临床开发中的新型抗生素，重点关注对产生金属-β-内酰胺酶（MBL）的耐碳青霉烯革兰阴性菌（CR-GNB）具有体外活性的药物：目前，只有少数几种已获批准的药物对产甲氧苄氨嘧啶的革兰氏阴性菌（CR-GNB）具有活性，无论是单独使用还是联合使用。如果监管机构在正在进行的（某些药物已经完成的）第三阶段研究中取得良好结果并予以批准，一些新型的β-内酰胺/β-内酰胺酶抑制剂（BL/BLI）组合药物可能会在未来几年内上市，成为治疗产生 MBL 的 CR-GNB 感染的额外重要选择。小结：通过良性的抗菌药物管理框架改进这些新型药物的使用，既能保证有效治疗需要使用这些药物的感染，又能在不必要时避免使用这些药物，这仍然是一个不容忽视的重大挑战。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Opinion in Infectious Diseases 医学-传染病学

CiteScore

6.70

自引率

2.60%

发文量

121

审稿时长

6-12 weeks

期刊介绍： This reader-friendly, bimonthly resource provides a powerful, broad-based perspective on the most important advances from throughout the world literature. Featuring renowned guest editors and focusing exclusively on two topics, every issue of Current Opinion in Infectious Disease delivers unvarnished, expert assessments of developments from the previous year. Insightful editorials and on-the-mark invited reviews cover key subjects such as HIV infection and AIDS; skin and soft tissue infections; respiratory infections; paediatric and neonatal infections; gastrointestinal infections; tropical and travel-associated diseases; and antimicrobial agents.